Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Silence Therapeutics PLC(SLN)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for SLN
09/25/2026: SLN (2-star) is currently NOT-A-BUY. Pass it for now.
Silence Therapeutics is a clinical-stage biotechnology company that specializes in developing siRNA-based gene silencing therapies for cardiovascular and hematological conditions. The company's core strength lies in its mRNAi GOLD platform, which enables precise drug delivery to the liver, validated through several strategic partnerships with major pharmaceutical players. While these collaborations offer significant long-term growth opportunities, the company carries substantial execution and clinical development risks, as it currently lacks commercialized products. The stock is best suited for risk-tolerant investors looking for exposure to genetic medicine, with key developments to monitor including clinical data readouts and ongoing partnership milestones.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high-growth potential driven by clinical milestones but carries significant development risk. |
| Momentum investor | Mixed fit | The stock can experience significant volatility driven by news-flow surrounding clinical trials. |
| Value investor | Weak fit | The company lacks current earnings or traditional valuation metrics, making it unsuitable for value strategies. |
| Dividend investor | Weak fit | There is no dividend policy, as all resources are dedicated to R&D. |
| Low-risk investor | Weak fit | Clinical-stage biotech investments involve high binary risks and price volatility. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock price is highly sensitive to binary clinical data readouts. |
| Valuation risk | High | Determining intrinsic value is difficult without commercial products or predictable revenue. |
| Competition risk (RNA therapeutic competition) | High | The company faces competition from better-funded firms with more advanced pipelines. |
| Business quality | Medium | While the technology is innovative, the company is still validating its clinical utility. |
| Dividend income | Low / none | The company does not generate the cash flow necessary to support dividends. |
| Execution risk | High | Success depends entirely on the successful completion of complex, late-stage clinical trials. |
Price Behavior
Hockey-Stick Growth
The stock demonstrates a Hockey-Stick Growth price path pattern.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 118.91% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 694.88M USD | Price to earnings Ratio - | 1Y Target Price 33 |
Price to earnings Ratio - | 1Y Target Price 33 | ||
Volume (30-day avg) 792.4K shares | Beta 1.44 | 52 Weeks Range 4.19 - 17.58 | Updated Date 09/26/2026 |
52 Weeks Range 4.19 - 17.58 | Updated Date 09/26/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.29 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Strategic R&D Partnerships | Collaborations where Silence receives upfront payments, milestone fees, and potential royalties for using its mRNAi GOLD platform. | The company is paid by larger pharmaceutical firms to develop drugs using its technology, which provides non-dilutive capital. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 673.91M | Price to Sales(TTM) 1129.89 |
Enterprise Value 673.91M | Price to Sales(TTM) 1129.89 | ||
Enterprise Value to Revenue 1095.78 | Enterprise Value to EBITDA -5.78 | Shares Outstanding 62.15M | Shares Floating 37.84M |
Shares Outstanding 62.15M | Shares Floating 37.84M | ||
Percent Insiders 7.97 | Percent Institutions 39.68 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Silence Therapeutics PLC
Exchange NASDAQ | Headquarters - | ||
IPO Launch date 2020-09-08 | Interim CEO & Chairman of the Board Mr. Iain Gladstone Ross B.Sc., BSc (Hons), C.DIR, CH.D | ||
Sector Healthcare | Industry Biotechnology | Full time employees 88 | |
Full time employees 88 | |||
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.